PubMed Health⌕ Search

Biomedical subjects

S K Kulkarni

Publications and source records attributed to S K Kulkarni.

At least 109 records · Page 6Linked to original sources

Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan.

Growing evidence has indicated the existence of a brain renin angiotensin system and its possible interaction with other putative neurotransmitters and their receptors. In the present study, the effect of losartan, an AT1 receptor antagonist, was studied on the motor functions involving the dopaminergic system. Losartan (5-30 mg/kg) per se decreased locomotor activity without producing motor toxicity. It partially reversed the apomorphine-induced hyperlocomotion and stereotypy in mice, and potentiated neuroleptic-induced catalepsy in rats. On chronic administration (once daily for 21 days) losartan failed to block apomorphine-induced hyperlocomotion, but the inhibition of stereotypic response and potentiation of neuroleptic-induced catalepsy remained unaltered. These observations suggest that losartan inhibited the release of dopamine through AT1 receptor and also suggest the existence of a compensatory mechanism in certain brain region concerned with dopamine motor function.

Angiotensin Receptor Antagonists↗

Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory.

In the present study we have shown the potential memory enhancing property of losartan, a selective Ang II AT1 receptor antagonist. Nootropic activity of losartan in mice was assessed by using passive avoidance step-down task and elevated plus-maze as a measure of short-term working and spatial memory respectively. Losartan at higher dose (10 mg/kg i.p) improved the basal performance in retention testing in both the test paradigms. Prior administration of losartan also attenuated retention deficit induced by scopolamine (0.3 mg/kg i.p). Moreover, physostigmine (0.05 mg/kg i.p) potentiated memory enhancing properties of losartan administered at lower dose (5 mg/kg i.p). On the basis of above observations it is concluded that the memory enhancing properties of losartan can be attributed to increased cholinergic activity.

Angiotensin Receptor Antagonists↗

Inhibition of neuronal nitric oxide synthase (n-cNOS) reverses the corticotrophin-induced behavioral effects in rats.

The nitric oxide (NO) synthase inhibitor NG-monomethyl-L-arginine (N-NMMA) and the competitive substrate for NO synthase L-arginine were used to determine the role of endogenous NO on the behavioral and neuroendocrine responsiveness following systemic corticotrophin in dexamethasone-suppressed rats. Corticotrophin (50-200 mU/kg, s.c.) dose-dependently decreased behavioral activity in the actimeter and produced significant anxiolytic and anti-risk activity in the plus-maze behavior test, without affecting systolic blood pressure. Rats given corticotrophin showed significant increased plasma corticosterone and reduced adrenal ascorbic acid level. These behavioral and adrenal responses of corticotrophin were dose dependently blocked by metyrapone (20 and 50 mg/kg, i.p.), an inhibitor of steroid 11beta-hydroxylase in adrenal and neural tissues that block steroidogenesis. Intracerebroventricular administration of L-NMMA (20 microg/rat in 10 microl) significantly prevented the behavioral hypoactivity and anxiolytic-like responses of corticotrophin without influencing the adrenal responsiveness. The effect of L-NMMA was completely reversed by preadministration of L-arginine (300 mg/kg, i.p.). These results suggest that neuronal nitric oxide pathway plays an important modulating role in the behavioral effects of corticotrophin by mechanisms other than those involving cardiovascular effects.

Adrenocorticotropic Hormone↗

Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin-specific T cells.

In the present study, we describe the potential role of melatonin, a pineal hormone, in regulating the activation of the antigen-specific T cell response. Melatonin encouraged the proliferation of Th cells and improved their ability to secrete IL-4, but down-regulated the levels of IL-2 and interferon-gamma (IFN-gamma). Melatonin, however, could not exert any influence on the T cells of unprimed mice. On studying the regulation of subclass of IgG isotype, melatonin specifically enhanced the secretion of antigen-specific IgG1 antibodies and decreased the yield of IgG2a isotype. The results suggest that melatonin possibly acts by selectively activating a Th2-like immune response.

Animals↗

Evidence of GABAergic modulation in melatonin-induced short-term memory deficits and food consumption.

Many of the pharmacological effects of melatonin have been found to be similar to those of benzodiazepines. In the present study, we analyzed the role of melatonin on short-term memory retrieval on transfer latency in elevated plus maze and food consumption behavior, and the effects were compared with those of diazepam. Melatonin dose-dependently (10-100 mg/kg) produced short-term memory deficit and it potentiated diazepam- (1 mg/kg) induced cognitive deficit in mice. Flumazenil (1 and 4 mg/kg) could reverse enhancement in diazepam-induced memory deficit by melatonin. Chronic treatment with melatonin (10 mg/kg/7d) produced a similar profile in transfer latency on elevated plus maze compared with that of diazepam. In a food consumption behavior study, melatonin (25 and 50 mg/kg) produced a significant hyperphagic effect compared to control. Flumazenil (4 mg/kg) could significantly reverse the hyperphagic effects induced by diazepam (2 mg/kg), but would be insignificant with regard to that due to melatonin. These findings provide further evidence that some of the pharmacological effects of melatonin are comparable with those of diazepam and may involve central GABAergic mechanism.

Animals↗

Protective effect of clozapine against pentylenetetrazol convulsions and kindling.

The atypical antipsychotic clozapine treatment (at high doses) has been reported to be associated with tremors. However, antitremor effects of clozapine have also been reported in Parkinsonian patients. Recently, we reported the protective effects of acute clozapine against pilocarpine-induced status epilepticus (SE). With this background, this study was designed to investigate the possible protective effect of clozapine against acute chemoconvulsions and kindling seizures produced by pentylenetetrazol (PTZ) in mice. Various doses of clozapine (1.0, 2.5, 5.0 and 7.5 mg) offered different degrees of protective effects against PTZ (80 mg) challenge, and the maximum protection was observed with the 2.5 mg dose as it delayed the onset of jerks, clonus, tonic extensor phase and reduced mortality. Animals chronically pretreated with clozapine (2.5, 7.5 and 15.0 mg) for 8 days when challenged by PTZ (50 and 80 mg) on the 8th day also showed protection. Repeated administration of PTZ at a subconvulsive dose (30 mg/kg, i.p, three times a week, for 9 weeks) produced kindled seizures in over 80% of the mice. Pretreatment with clozapine (1 or 5 mg) prevented the behavioral manifestations (motor seizures) as well as the development of kindling. The effect was compared with GABA (200 mg) and diazepam (1 mg), a known anticonvulsant drug.

Animals↗

Antinociceptive effect of sumatriptan in mice.

Antinociceptive effect of the antimigraine drug sumatriptan (5-HT1A agonist) was studied against acetic acid-induced writhing in mice. Sumatriptan produced the effect in a dose-dependent manner (1, 5, 10 and 20 mg/kg, s.c.). Naloxone (1 mg/kg i.p.) an opiate antagonist failed to reverse sumatriptan-induced antinociception. Cholinomimetic physostigmine (0.05 mg/kg, i.p.) potentiated and the muscarinic antagonist atropine (5 mg/kg, i.p.) blocked the antinociceptive effect of sumatriptan, respectively. The antinociceptive effect of sumatriptan was compared with an another 5-HT agonist (5-HT1A) buspirone which also produced antinociception. Like sumatriptan-analgesia, the buspirone response was also potentiated by physostigmine in atropine sensitive way. Further, buspirone potentiated the analgesic effect of sumatriptan. These observations suggest that 5-HT1A agonists produce antinociception possibly by modulating central cholinergic activity.

Animals↗

Development of self-sustaining limbic status epilepticus by continuous ventral hippocampal stimulation followed by low dose pilocarpine in rats.

Sequential treatment of rats with low doses of lithium and pilocarpine, a high dose of pilocarpine, or continuous hippocampal stimulation [CHS] (9 epochs, 10 min each) is reported to result in status epilepticus (SE). We report a novel method to establish SE based on continuous ventral hippocampal stimulation (5 epochs) followed by low dose pilocarpine (40 mg/kg) challenge. Motor limbic seizures occured in all the control rats. The latency to spike activity was 15 +/- 1 min after pilocarpine administration. Ventral hippocampal [VHc] and cortical EEG recordings were used to monitor the protective effect of diazepam (5 mg/kg). Except phenobarbital, all the three drugs completely prevented all the phases of seizure activity. Initiation of spikes was significantly prolonged by phenobarbital pretreatment. Further study on the characteristics of these convulsions offers a unique possibility for the recognition of brain regions, pathways, and neurotransmitters engaged in the spread of seizures in this model.

Animals↗

Preferential blockade by clozapine of hyperlocomotion induced by non-competitive NMDA antagonist MK-801.

Effect of clozapine on MK-801-induced hyperlocomotion and stereotypy as well as open field behavior was studied. Clozapine (0.1-7.5 mg/kg) dose-dependently blocked MK-801(0.5 mg/kg)-induced stereotypy. Both total and ambulatory responses were blocked by even the lower doses (0.1-0.5 mg/kg) of clozapine. In open field test, clozapine selectively blocked hyperambulation induced by MK-801 (0.1 mg/kg) whereas it potentiated MK-801 (0.1 mg/kg)-induced stereotypy at all the doses used. Haloperidol (0.25 and 0.5 mg/kg) and SCH 23390 (0.5 and 1 mg/kg) showed a dose-dependent effect on MK-801-induced behaviors while sulpiride (25 and 50 mg/kg) failed to modify MK-801-induced open field behavior. This study supports the preferential effect of clozapine on dopamine receptors located in mesolimbic area and further suggests the possibility of using open field behavior induced by MK-801 as a model for studying atypical antipsychotics.

Analysis of Variance↗

Central nervous system depressant activities of melatonin in rats and mice.

Melatonin (10 and 20 mg/kg) potentiated pentobarbitone (45 mg/kg) induced hypnosis; it (50 and 100 mg/kg) decreased both total and ambulatory activity; produced (10, 25 and 50 mg/kg) hypothermia and possessed (10-400 mg/kg) significant analgesic property both in tail-flick and acetic acid-induced writhing tests. Melatonin in low dose (10 mg/kg) significantly reduced the forced-swimming induced immobility period per se and also reserpine induced immobility. While the antinociceptive effect of melatonin was sensitive to reversal by naloxone (2 mg/kg), other CNS depressant profile resembled the effects of benzodiazepines.

Animals↗

Anticonvulsant profile of Siotone granules, a herbal preparation.

Siotone granule, a herbal psychotropic formulation was tested for its effectiveness in various models of convulsions in animals. S. granule (100 and 200 mg/kg) offered significant protection against pentylenetetrazol-, maximal electroshock- and strychnine-induced convulsions. In hypoxic stress-induced convulsions only 200 mg/kg was effective. It also reduced percent mortality per se and rendered total protection when given in combination with sub-protective dose of diazepam (0.5 mg/kg) and MK-801 (0.1 mg/kg) against pentylenetetrazol-induced convulsions. The anticonvulsant action of S. granule was blocked by flumazenil (4 mg/kg) suggesting the involvement of GABAergic mechanism.

Animals↗

Chronic neurosteroid treatment prevents the development of morphine tolerance and attenuates abstinence behavior in mice.

The effect of neurosteroids on the development of morphine tolerance and dependence was examined in mice. Development of tolerance to the antinociceptive effect of morphine sulfate (10 mg/kg, twice daily for 9 days) was measured in the tail-flick test and dependence was assessed from naloxone (2 mg/kg)-precipitated withdrawal jumps on day 10 of testing. Concomitant chronic administration of neurosteroids, allopregnanolone (0.5 mg/kg), pregnenolone sulfate (2 and 5 mg/kg) or dehydroepiandrosterone sulfate (2 and 5 mg/kg), followed by morphine (10 mg/kg) prevented the development of tolerance to the antinociceptive effect of morphine and suppressed the naloxone-precipitated withdrawal jumps. In contrast, dehydroepiandrosterone acetate (5 mg/kg) failed to modulate the morphine tolerance and dependence. The inhibitory effect was also seen upon concomitant administration of a neurosteroid precursor, progesterone (1-10 mg/kg), and a mitochondrial diazepam binding inhibitor receptor agonist, 4'-chlordiazepam (0.25-1 mg/kg), while an adrenocorticosteroid, hydrocortisone (1 and 10 mg/kg), failed to do so. However, acute treatment with these neurosteroids was not associated with any decrease in withdrawal jumping behavior in morphine-dependent mice. Neurosteroids themselves, at doses employed in the study, did not exert any effects on antinociception. These results support a role for neurosteroids in the development of tolerance to and dependence on morphine and suggest the potential utility of specific neuroactive steroids in its treatment.

Analgesics, Opioid↗

Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice.

This study examined the effects of neurosteroids on the behavior of mice in the mirrored chamber test of anxiety, and determined the potential mechanisms by which neurosteroids alter the behavior in animal models of anxiety. Allopregnanolone (AP) (0.5 and 1 mg/kg) and pregnenolone sulfate (PS) (0.5 and 2 mg/kg) significantly reduced the latency to enter the chamber, and increased both number of entries and total time spent in the chamber in a dose-dependent manner, without affecting the spontaneous locomotor activity. In contrast, dehydroepiandrosterone sulfate (DHEAS) (1 and 2 mg/kg) increased motor activity and caused an anxiogenic response, i.e., an increase in latency to enter the mirrored chamber, and a decrease in the number of entries and time spent in the chamber. Progesterone (PROG) (1-10 mg/kg), a neurosteroid precursor, and 4'-chlordiazepam (4'-CD) (0.25-1 mg/kg), a specific ligand for the mitochondrial diazepam binding inhibitor (DBI) receptor (MDR), produced a clear dose-dependent anxiolytic response in the mirrored chamber. The AP-, PROG- and 4'-CD-elicited anxiolytic behavior was blocked by picrotoxin (1 mg/kg), a GABA-A chloride channel antagonist, but not by flumazenil (2 mg/kg), a selective benzodiazepine (BZD) antagonist. In contrast, the anxiolytic effect of PS was not blocked by picrotoxin. The 4'-CD-induced anxiolytic effect was prevented by pretreatment with PK11195 (2 mg/kg), a selective partial MDR antagonist. Nifedipine (2 and 5 mg/kg), a dihydropyridine-type Ca2+ channel blocker, produced a flumazenil-resistant anxiolytic effect. Combined administration of nifedipine (2 and 5 mg/kg) and PS (0.5 and 2 mg/kg) exerted a significant additive effect in the mirrored chamber test. The potent anxiolytic effect of dizocilpine (0.5 and 1 mg/kg), an NMDA receptor antagonist, was blocked by pretreatment with DHEAS (2 mg/kg). Neurosteroids evoked changes in mirrored chamber activities resembling those elicited by triazolam (0.25 and 0.5 mg/kg). However, these effects were seen at doses that did not markedly affect locomotor activity, thereby suggesting these changes in behavior represent anxiolytic actions. Together, these results provide evidence for differential behavioral actions of the neurosteroids AP, PS and DHEAS in the mirrored chamber test of anxiety. The anxiolytic effect of PROG may be imputed to its metabolism to neurosteroid AP, while the 4'-CD-induced anxiolytic response is related to its MDR-stimulated neurosteroidogenesis and subsequent modulation of GABA-A receptor. Further, these differential effects reaffirm the contention that neurosteroids could be involved in the homeostasis of stress response.

Animals↗

Inhibition of morphine tolerance and dependence by Withania somnifera in mice.

Chronic treatment with Withania somnifera (Ws) (family: Solanaceae, 100 mg/kg) commercial root extract followed by saline on days 1-9 failed to produce any significant change in tailflick latency from the saline pretreated group in mice. However, repeated administration of Ws (100 mg/kg) for 9 days attenuated the development of tolerance to the analgesic effect of morphine (10 mg/kg). Ws (100 mg/kg) also suppressed morphine-withdrawal jumps, a sign of the development of dependence to opiate as assessed by naloxone (2 mg/kg) precipitation withdrawal on day 10 of testing.

Administration, Oral↗

Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model.

The profile of action of ondansetron was assessed in a novel animal model of anxiety. The mirrored chamber is a nonpunishing quantitative model of anxiety which measures approach-conflict behavior. Ondansetron in all the doses tested (0.01, 0.1 and 1 mg/kg i.p.) showed significant anxiolytic action as compared to naive mice, but it was less potent as compared to a well-known anxiolytic, diazepam (1 mg/kg). These results suggest that ondansetron has anxiolytic efficacy in nonconflict paradigms of anxiety, a response not mediated by the conventional neurotransmitter receptors. GABA-benzodiazepine as flumazenil (4 mg/kg), a benzodiazepine receptor antagonist, failed to reverse the behavioral parameters evoked by ondansetron.

Animals↗

Modulation of lithium-pilocarpine-induced status epilepticus by adenosinergic agents.

Effect of adenosinergic agents were investigated in lithium-pilocarpine-induced status epilepticus (SE) in rats. Adenosinergic agents such as adenosine (50, 100 mg/kg), 2-choloroadenosine (1, 2 mg/kg), carbamazepine (20, 80 mg/kg), N6-cyclohexyladenosine (1, 2 mg/kg) and dipyridamole (10, 20 mg/kg) produced theophylline-sensitive protective effects as they dose-dependently prolonged the latencies for onset of forelimb clonus with rearing. Pretreatment with Ro 5-4864 (20 mg/kg i.p.) did not offer any protection. These results indicate the possible involvement of adenosinergic mechanism in preventing lithium-pilocarpine-induced SE and mortality.

2-Chloroadenosine↗

Dopaminergic modulation of lithium/pilocarpine-induced status epilepticus in rats.

The effects of selective dopaminergic agonists and antagonists on epileptic activity were tested in rats using the lithium/pilocarpine seizure model. Systemic administration of the D1 agonist SKF-38,393 reduced the latency of onset of forelimb clonus with rearing, whereas the D1 antagonist SCH-23,390 and the D2 agonist B-HT 920 prevented the convulsive activity in a dose-dependent manner. Mixed agonists like apomorphine offered partial protection. Haloperidol (D1, D2 blocker, with antimuscarinic property) reduced the threshold for convulsions. The effects of SKF-38,393 and B-HT 920 could be partially blocked by pretreating the rats with SCH-23,390 and sulpiride, respectively. Neither D1 nor D2 antagonists could alter the limbic stereotypies induced by lithium/pilocarpine. These results indicate that dopamine receptor subtypes exert opposite effects on the regulation of convulsive activity. Lipid peroxidation levels (MDA formed) in rat brain homogenates were found to be concomitant with the development of epileptiform activity.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗